A voluntary nationwide recall of a specific lot of Xanax XR has been announced after quality testing showed the tablets did not meet FDA dissolution requirements.
According to the FDA Enforcement Report, Viatris, Inc. recalled one lot of alprazolam extended‑release tablets (Xanax XR). The recall, initiated March 17, covers 3 mg tablets sold in 60‑tablet bottles, lot number 8177156, with an expiration date of February 28, 2027. The tablets were manufactured in Ireland and distributed in the U.S. by Viatris Specialty LLC in Morgantown, West Virginia.
Dissolution testing evaluates how quickly and completely the active ingredient is released from a tablet. For extended‑release products such as Xanax XR, proper dissolution is essential to ensure the medication releases gradually and maintains steady symptom control. The recalled lot failed to meet those dissolution specifications, which could mean the body absorbs less than the intended amount and the drug may be less effective at treating anxiety or panic symptoms.
The FDA classified this as a Class II recall, indicating that use of the product could cause temporary or medically reversible adverse health consequences and is unlikely to result in serious long‑term harm. Experts emphasize this is a manufacturing quality issue rather than a toxicity concern: the medication is not expected to be harmful, but it might not provide the expected therapeutic effect.
Clinicians warn patients not to stop taking benzodiazepines abruptly because sudden discontinuation can cause withdrawal. If you possess tablets from lot 8177156, continue taking them as prescribed and contact your prescriber promptly to arrange a replacement prescription or to discuss alternative treatments. You may also contact Viatris or review the FDA recall notice for the latest information. As of April 8, 2026, the recall remains ongoing and no formal FDA press release has been issued.